Lv3
280 积分 2024-02-01 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
5小时前
已完结
Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
2个月前
已完结
Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
2个月前
已完结
Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN
2个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2个月前
已完结
Toward personalized treatment approaches for non-small-cell lung cancer
2个月前
已完结
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
4个月前
已完结
Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
4个月前
已完结
Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
4个月前
已完结
皖公网安备34019202002308
